Myelodysplastic Syndrome

Myelodysplastic Syndromes, which were previously considered rare, are currently known as some of the most frequently occurring hematological neoplasms, perhaps affecting over 30,000 patients each year within the U.S. The nation's regulatory permission of lenalidomide, azacitidine and decitabine, from 2004 to 2006 appeared to indicate a new age in the improvement of therapy for disease modification for these disorders. However, no indications of drugs being approved for MDS appear to be present in the U.S. for the past 8 years. There are no curative drugs available so far.

However, some compounds under development may be approved soon. Consequently, diagnoses of MDS are still quite a heavy load, both on patients and medical care systems (Bejar & Steensma, 2014). Background Myelodysplastic Syndromes are a set of distinct disorders of the bone marrow that prevent the victim's bone marrow from producing sufficient fit blood cells. The disorders are often called "failure of the bone marrow." MDS is mainly a disorder for elderly people (most of the victims are more than 65 years old).

However, even younger people can have the disease. In order to have a better understanding of MDS, one needs to first look at some basics facts about blood and bone marrow. The human bone marrow acts as a manufacturer of three blood cell types: the white and red cells, and the platelets. Good bone marrow creates undeveloped blood cells known as progenitor cells, blasts, or stem cells that typically grow into mature, completely functional white cells, platelets, and red cells.

In MDS, the stem cells could fail to grow, and they may accumulate within the patient's bone marrow. Alternatively, the stem cells' life span may be shortened, leading to abnormally few developed blood cells circulating (MDS Foundation, 2014-2017). Besa, Nagalla and Krishnan (2016) state that MDS could involve a single, two or even three (all) of the cell lineages of myeloid hematopoiesis; which are megakaryocytic, erythrocytic or granulocytic. This is determined by the stage and subtype of the disorder.

The heterogenous nature of MDS shows that the course of the illness involves a sequence of cytogenetic occurrences. In a small cluster of MDS patients, acquiring more genetic abnormalities leads to the conversion of the disease into AML (acute myelogenous leukemia). Therefore, even though MDS is clonal, it is also classified as premalignant. Many patients wonder if MDS can be classified as a kind of cancer. The disease is indeed cancer. Cancer is caused by a change/mutation to an ordinary cell that leads to growth of abnormally functioning cells.

Nonetheless, the impact of an illness on the quality of life of a patient matters much more than the word that describes that illness. MDS can develop slowly and cause less interference with the life of a patient, than other illnesses, not classified as cancer (Leukemia and Lymphoma Society, 2016). Symptoms According to The MDS Foundation (2014-2017), Myelodysplastic syndromes, in most cases do not show any early symptoms or signs. Symptoms and signs could be caused by either the disorder or other health problems.

A regular blood test could show a reduction in the number of red cells, or low levels of hematocrit, at times also a reduction in the number of platelets or white cells. In some cases, one may have less than normal number of platelets and white cells and normal level hematocrit. Nonetheless, some patients, especially those who have fewer than usual blood cells, have definite symptoms. Therefore, symptoms differ by the type of blood cell involved and the blood cell count level.

Low Red Cell Count (ANEMIA) Most patients are usually suffering from anemia when it is first discovered that they have MDS. Anemic patients have a consistently low level of hematocrit (the amount of red cells in the body) or consistently low hemoglobin levels (the protein in blood in charge of transporting oxygen to tissues in the body). People suffering from anemia, in general, experience fatigue. They are constantly tired and weak. The severity of anemia varies with patients.

In mild cases, the victims may be well or maybe a little fatigued. For patients with moderate anemia, there may be fatigue, palpitations of the heart, pale skin and difficulty in breathing. In severe cases, most of the patients look pale and suffer chronic overpowering fatigue as well as difficulty in breathing. Since severe anemia leads to a reduction in the flow of blood to the heart and older victims have a higher probability of having cardiovascular symptoms, such as chest pain.

Even though chronic anemia has a low mortality rate, it can lead to drastic reduction of the victim's quality of living (MDS Foundation, 2014-2017). Low White Cell Count (NEUTROPENIA) A reduction in the number of white cells leads to a reduction in the ability of the body to fight bacterial infection.

Neutropenic patients are likely to be vulnerable to infections of the skin, sinus infections (with such symptoms as nasal congestion), infections of the lungs (with such symptoms as difficulty in breathing and cough), or infections of the urinary tract (with symptoms such as frequent and painful urination). These infections may cause fever (MDS Foundation, 2014-2017). Low Platelet Count (THROMBOCYTOPENIA) Thrombocytopenic patients have a high tendency of getting bruises and bleeding even due to minor scrapes and bumps.

It is common for them to nosebleed and have bleeding gums; especially after handling their teeth. Before any dental work, it is important to talk to your hematologist. They may recommend prophylactic antibiotic consumption, which is recommended as bleeding and infection may be a danger to most people with MDS (MDS Foundation, 2014-2017). Diagnosis Accoring to Germing, Kobbe, Haas and Gattermann (2013), most times, the people who take part in diagnosing the disease are family physicians. They identify anemia when conducting routine tests.

In other cases, MDS is found based on blood tests conducted to examine the problem, which led to anemic symptoms. After having ruled out the most common anemia causes like lack of iron, folic acid and vitamin B12 deficiency, as well as hemolysis, it is important to ask the patient to see a hematologist, who should conduct further investigation. Specifically, having bi- /pancytopenia (around 30%) may be a red flag, which may be an indicator of bone marrow illness.

If the number of blood cells is normal and there is normal differential cell amount, there are extremely low chances of a person having MDS. Patients who may have been through chemotherapy to treat other diseases, whether malignant or benign, particularly with alkylating medication (ifosfamide, cyclophosphamide, carmustine and dacarbazine among other drugs) and/or radioiodine or radiation treatment before have a greater chance of having MDS: about 10% of people with MDS got the illness after going through radiation or cytotoxic treatment.

Occupational history along with any details to the liability insurance organization of the employers seem to be significant in case of a probability that there could have been past (long-term) usage of benzole, as it puts patients at a risk of getting MDS. Once nonhematological and hematological differential diagnoses are ruled out, thorough cytomorphological examination of bone marrow and blood are important, ideally conducted by a skilled pathologist or hematologist. At times, experienced diagnosticians are not able to make a clear diagnosis.

Therefore, repeat investigations of the bone marrow can at times be important in case the cytopenia is persistent (Germing, Kobbe, Haas & Gattermann, 2013). Low-Risk and High-Risk MDS Doctors describe MDS patients as either "high risk" or "low risk." For low-risk patients, the disease progresses gradually, the unusual blasts that get into your bloodstream work like ordinary blood cells. In addition, the disease only causes mild-average anemia.

For high-risk patients, on the other hand, the platelets, red cell and white cell levels are very low and the blast cells fail to grow into working platelets, red cells and white cells. In addition, people with over 20% blast cells within the bone marrow are said to have AML (acute myeloid leukemia) (Leukemia and Lymphoma Society, 2016). Risk Factors Risk factors are those things that increase the risk of a person getting an illness.

However, risk factors do not automatically mean that the person will get ill, and not having them does not rule out the possibility of a person getting sick (Leukemia and Lymphoma Society, 2016). Most MDS patients are found to have primary MDS, which is also referred to as de novo MDS. There is no clear cause of primary MDS in many patients. One of the known risk factors of MDS is recurrent exposure to benzene, the chemical, which leads to DNA damages on the stem cells.

The best known source of this chemical is cigarette smoke. There is not enough information available for determining if smoking leads to increased risk of getting MDS. Nonetheless, it is recognized that smokers have a 1.6 times higher chance of getting AML than non-smokers. Benzene can also be found in specific industrial settings. Harsh rules regarding its use, nevertheless, have led to a decrease in the exposure of the chemical at work (Leukemia and Lymphoma Society, 2016). Some MDS patients are found to have secondary MDS, which is treatment-related.

This kind of MDS develops after radiotherapy or chemotherapy for treating other types of cancer like breast cancer, lymphoma or myeloma. However, only a small proportion of patients exposed to radiotherapy or chemotherapy that get MDS (Leukemia and Lymphoma Society, 2016). It should be noted that MDS is neither hereditary nor communicable. In fact, cases of family members, finding siblings with the disease is very rare occurrence, if at all (MDS Foundation, 2014-2017).

Treatment According to Germing, Kobbe, Haas and Gattermann (2013), doctors make treatment plans based on the patient's condition: whether high risk or low risk. A simple principle states that, for patients with low-risk MDS, the first line of treatment seeks restoration or maintenance of life quality, while.